GENOTROPIN (somatropin for injection) should not be used when there is any evidence of neoplastic activity. Intracranial lesions must be inactive and antitumour therapy complete prior to the institution of therapy. GENOTROPIN should be discontinued if there is evidence of tumour growth.
Growth hormone should not be used for growth promotion in children with fused epiphyses.
Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.
GENOTROPIN is contraindicated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure. (see WARNINGS AND PRECAUTIONS).
GENOTROPIN is contraindicated in patients with a history of hypersensitivity to any of its components.
GENOTROPIN is contraindicated in patients with Prader-Willi syndrome who have uncontrolled diabetes, or active psychosis, or have active cancer.
GENOTROPIN is contraindicated in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients. (see SERIOUS WARNINGS AND PRECAUTIONS).
Certain formulations of growth hormones contain metacresol as a preservative. These formulations should not be used by patients with a known sensitivity to these preservatives (see WARNINGS AND PRECAUTIONS, General).
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:
1 866 723-7111.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at